Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 1 March 1996:
Vol. 271. no. 5253, pp. 1227 - 1228
DOI: 10.1126/science.271.5253.1227a
Prev | Table of Contents | Next

News & Comment

Jon Cohen

Many AIDS researchers fear that industry has lost interest in producing new vaccines to prevent the deadly disease. One indication: At this year's Annual Conference on Advances in AIDS Vaccine Development only one new vaccine strategy was deemed sufficiently promising to merit an oral presentation. The National Institute of Allergy and Infectious Diseases (NIAID) is now trying to reduce some of the uncertainty that companies face. It is setting specific criteria for expanding clinical vaccine testing so that companies know exactly what needs to be accomplished to get NIAID funding for wider trials. But leading AIDS researchers are questioning how the criteria were set. Meanwhile, Vice President Gore has convened a meeting between industry and government AIDS officials to see what can be done to maintain industry interest in developing vaccines and other AIDS drugs and preventatives.




To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)